Note 14 - Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)

12 Months Ended

Apr. 30, 2014

Tables/Schedules

Schedule of Segment Reporting Information, by Segment

	Fiscal year Ended April 30,
	2014	2013
Revenues:
Chinese medicine – third party	$     2,429,468	$     2,614,672
Chinese medicine – related party	0	0
Total Chinese medicine	2,429,468	2,614,672
Stevioside – third party	6,738,685	4,684,709
Stevioside – related party	3,705,504	2,503,147
Total Stevioside	10,444,189	7,187,856
Total segment and consolidated revenues	$   12,873,657	$     9,802,528
Interest expense:
Chinese medicine	$                     0	$                     0
Stevioside	120,144	27,793
Corporate and other	0	0
Total segment and consolidated interest expense	$        120,144	$          27,793
Depreciation and amortization:
Chinese medicine	$        164,122	$        445,318
Stevioside	2,000,460	1,401,442
Corporate and other	0	0
Total segment and consolidated depreciation and amortization	$     2,164,582	$     1,846,760
(Loss) income before income taxes:
Chinese medicine	$         (52,141)	$        207,879
Stevioside	(2,961,882)	(2,451,730)
Corporate and other	(51,798)	(1,730,289)
Total consolidated loss before income taxes	$   (3,065,821)	$   (3,974,140)